Hillhouse-backed Genor Biopharma reaches $1.8b market cap in HK IPO

Genor Biopharma, a Chinese commercial-ready biopharmaceutical firm backed by Hillhouse Capital, has reached a market capitalisation of HK$14 billion ($1.8 billion) after the company’s initial public offering (IPO) on the main board of the Hong Kong Stock Exchange (HKEX) on Wednesday.